Preclinical pharmacokinetic exploration of a novel osteoporotic quinazolinone-benzopyran-indole hybrid (S019-0385) using LC-MS/MS

Abstract

1. The current investigation was to develop and validate the LC-MS/MS method in order to analyse the various pharmacokinetic parameters of S019-0385. A sensitive, selective, and robust LC-MS/MS approach was established and validated for measuring S019-0385 in female mice plasma and tissue, using optimal multiple reaction monitoring (MRM) transition m/z 488.25/329.12 on positive mode. On a Waters Symmetry Shield C18 column, the analyte was separated using acetonitrile and deionised water with formic acid within 6 min at 0.7 mL/min. Linearity (R² ≥ 0.99) was observed across 0.195–100 ng/mL concentration range using linear least-squares regression.

2. Blood-to-plasma ratio and plasma protein drug binding (%) in mice and human was assessed and found to be less than 1 and >83%, respectively. Absolute bioavailability (%F) of S019-0385 in female Swiss mice was exhibited to be 6.90%. Percent dose excreted S019-0385 in unchanged form through urine and faecal was found to be less than 2% and 0.5%, respectively.

3. Following oral administration at 5 mg/kg, the concentration of S019-0385 in tissue distribution was found to be in the order of C small intestine > C bone > C lung > C spleen > C kidney > C liver > C heart > C brain.

Keywords:

• LC-MS/MS
• oral and IV pharmacokinetics
• bioavailability
• tissue distribution
• excretion

Acknowledgment

The authors are thankful to The Director, CSIR-Central Drug Research Institute for providing all the necessary facilities including animal house facility to complete the research work. Mukesh Kumar is also thankful to University Grants Commission New Delhi for providing the fellowship. CSIR-CDRI communication number for this manuscript is 10673.

Disclosure statement

The authors have no conflict of interest to declare.

Additional information

Funding

Mukesh Kumar is thankful to University Grants Commission, New Delhi for providing the fellowship. Fellowship Number: 19/06/2016(i)EU-V, 348226.